2.57% -0.3893

Bioage Labs Inc (BIOA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Bioage Labs Inc Stock (BIOA) Company Profile

Bioage Labs Inc

Healthcare (1131)

510-806-1445

5885 HOLLIS STREET, EMERYVILLE

Nächster Verdiensttermin

Neueste SEC-Einreichungen

BIOA's Discussions on Twitter

Vergleichen Sie BIOA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BIOA Bioage Labs Inc	12.84	474.36M	0	0	0	0.00
ZTS Zoetis Inc	125.46	55.45B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	15.62	49.25B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.01	45.02B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	30.60	35.81B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	492.45	20.98B	3.08B	1.24B	1.07B	25.61

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2025-10-22	Hochstufung	Citigroup	Neutral → Buy
2025-02-28	Eingeleitet	William Blair	Mkt Perform
2024-12-10	Herabstufung	Morgan Stanley	Overweight → Underweight
2024-12-09	Herabstufung	Citigroup	Buy → Neutral
2024-12-09	Herabstufung	Jefferies	Buy → Hold
2024-10-21	Eingeleitet	Citigroup	Buy
2024-10-21	Eingeleitet	Jefferies	Buy
2024-10-21	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten

Finanzdaten der Bioage Labs Inc-Aktie (BIOA)

Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Bioage Labs Inc-Aktie (BIOA) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0

Bioage Labs Inc (BIOA)

Bioage Labs Inc Stock (BIOA) Company Profile

Vergleichen Sie BIOA mit anderen Aktien

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten

Can BioAge Labs Inc. stock deliver sustainable ROEQuarterly Earnings Review & Maximum Profit Growth - bollywoodhelpline.com

BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile

BioAge Labs (NASDAQ:BIOA) Sets New 52-Week HighStill a Buy? - MarketBeat

Cash per share of BioAge Labs, Inc. – FWB:Y7G - TradingView — Track All Markets

BioAge Labs, Inc.(NasdaqGS: BIOA) added to NASDAQ Biotechnology Index - marketscreener.com

BioAge Labs announces positive phase 1 trial results - MSN

BioAge Labs (BIOA) Price Target Increased by 24.14% to 12.24 - Nasdaq

Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Catalysts & Real-Time Volume Trigger Notifications - Улправда

Can BioAge Labs Inc. stock continue upward trendMarket Activity Summary & Verified Momentum Stock Ideas - Улправда

Why BioAge Labs Inc. (Y7G) stock is listed among top recommendationsQuarterly Market Review & Risk Controlled Daily Trade Plans - DonanımHaber

What makes BioAge Labs Inc. stock attractive to growth fundsJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber

Can BioAge Labs Inc. stock withstand economic slowdown2025 Technical Overview & Technical Confirmation Alerts - DonanımHaber

How analysts rate BioAge Labs Inc. stock today2025 Volume Leaders & High Accuracy Investment Signals - DonanımHaber

Bioage Labs Earnings Notes - Trefis

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Globe and Mail

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool

Bioage Labs Stock Rockets 52% With 8-Day Winning Streak - Trefis

Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat

BioAge Labs CMO Paul D. Rubin Sells 18,000 Shares - TradingView — Track All Markets

[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan

Officer Rubin Files To Sell 18,000 Of BioAge Labs Inc [BIOA] - TradingView — Track All Markets

Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq

BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat

Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ

Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat

BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen - MarketBeat

BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView

Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView

BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa

How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser

BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria

Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser

Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser

How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser

Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks

Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛

Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView

Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser

Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ

BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com

BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq

BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - markets.businessinsider.com

BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets

Finanzdaten der Bioage Labs Inc-Aktie (BIOA)

Umsatz

Nettogewinn

Free Cashflow

ENV

Bioage Labs Inc-Aktie (BIOA) Insiderhandel

Ähnlich wie BIOA